We’re thrilled to journey to Nashville from March 29 to April 1 for the Society of Hospital Medicine Converge Conference 2026, the premier gathering for hospital medicine professionals.
As the healthcare landscape shifts toward a system-level approach to glycemic safety, Glooko will showcase how we’re redefining inpatient insulin management through the EndoTool Glucose Management System, developed by Monarch Medical Technologies, a Glooko Company, at SHM Converge booth 503.
With nearly one-third of hospitalized patients requiring glycemic support, the conversations we’re having with hospitalists emphasizes a shared goal: moving away from reactive, “one-size-fits-most” protocols and toward proactive, data-driven precision to meet newly required CMS reporting guidelines.
Assess Your Inpatient Insulin Workflows at Booth 503
With these mandatory CMS glycemic safety reporting now active, the need to ensure robust inpatient insulin management has moved to the center of the quality agenda. Visitors to our booth will have the opportunity to audit their hospital’s existing insulin workflows against new CMS guidelines in our five-minute CMS Glycemic Safety Readiness Assessment and discuss next steps with our team.
Transforming Diabetes Management from Hospital to Home
Beyond our technology, our presence at SHM Converge underscores Glooko’s broader mission to bridge the diabetes care gap between hospital and home. We know that effective diabetes management is a continuous journey that doesn’t end at discharge, and that’s why our acquisition of Monarch Medical Technologies and EndoTool was a pivotal step in advancing comprehensive inpatient and outpatient diabetes care.
Ready to Enhance Inpatient Diabetes Care?
Schedule a demo with our experts to learn how we can help your hospital meet the new CMS glycemic reporting requirements while delivering the high-quality, personalized care patients deserve.
EndoTool is developed and marketed by Monarch Medical Technologies, a Glooko Company. EndoTool is an FDA-cleared Class II medical device indicated for inpatient use as described in its Instructions for Use. Glooko’s diabetes management platform and EndoTool are currently independent solutions. Patient-specific refers to EndoTool’s ability to use available patient information within the hospital’s electronic medical record to provide individualized insulin dosing recommendations. Recommendations are intended to assist, not replace, clinical judgment. All treatment decisions remain the responsibility of the licensed healthcare provider.